These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 16856800)
1. Development of antibodies for cancer therapy. Wilkins DK; Mayer A Expert Opin Biol Ther; 2006 Aug; 6(8):787-96. PubMed ID: 16856800 [TBL] [Abstract][Full Text] [Related]
2. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Sharkey RM; Karacay H; Cardillo TM; Chang CH; McBride WJ; Rossi EA; Horak ID; Goldenberg DM Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7109s-7121s. PubMed ID: 16203810 [TBL] [Abstract][Full Text] [Related]
3. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model. Sharkey RM; Karacay H; Griffiths GL; Behr TM; Blumenthal RD; Mattes MJ; Hansen HJ; Goldenberg DM Bioconjug Chem; 1997; 8(4):595-604. PubMed ID: 9258460 [TBL] [Abstract][Full Text] [Related]
4. A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. Lin Y; Pagel JM; Axworthy D; Pantelias A; Hedin N; Press OW Cancer Res; 2006 Apr; 66(7):3884-92. PubMed ID: 16585217 [TBL] [Abstract][Full Text] [Related]
5. Development of new biotin/streptavidin reagents for pretargeting. Wilbur DS; Pathare PM; Hamlin DK; Stayton PS; To R; Klumb LA; Buhler KR; Vessella RL Biomol Eng; 1999 Dec; 16(1-4):113-8. PubMed ID: 10796993 [TBL] [Abstract][Full Text] [Related]
6. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose. Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198 [TBL] [Abstract][Full Text] [Related]
7. Constructs of biotin mimetic peptide with CC49 single-chain Fv designed for tumor pretargeting. Pavlinkova G; Batra SK; Colcher D; Booth BJ; Baranowska-Kortylewicz J Peptides; 2003 Mar; 24(3):353-62. PubMed ID: 12732332 [TBL] [Abstract][Full Text] [Related]
8. Pre-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using streptavidin-CC49 monoclonal antibody and 90Y-DOTA-biotin. Domingo RJ; Reilly RM Nucl Med Commun; 2000 Jan; 21(1):89-96. PubMed ID: 10717908 [TBL] [Abstract][Full Text] [Related]
9. Systems biology and the mathematical modelling of antibody-directed enzyme prodrug therapy (ADEPT). Varner JD Syst Biol (Stevenage); 2005 Dec; 152(4):291-302. PubMed ID: 16986273 [TBL] [Abstract][Full Text] [Related]
10. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Reagent development. Karacay H; Sharkey RM; Govindan SV; McBride WJ; Goldenberg DM; Hansen HJ; Griffiths GL Bioconjug Chem; 1997; 8(4):585-94. PubMed ID: 9258459 [TBL] [Abstract][Full Text] [Related]
11. Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies. Govindan SV; Griffiths GL; Hansen HJ; Horak ID; Goldenberg DM Technol Cancer Res Treat; 2005 Aug; 4(4):375-91. PubMed ID: 16029057 [TBL] [Abstract][Full Text] [Related]
12. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT). Biela BH; Khawli LA; Hu P; Epstein AL Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121 [TBL] [Abstract][Full Text] [Related]
13. Immunotoxins: a review of their use in cancer treatment. Aruna G J Stem Cells Regen Med; 2006; 1(1):31-6. PubMed ID: 24692859 [TBL] [Abstract][Full Text] [Related]